ATE465261T1 - Integrin-gekoppelte kinase, ihre hemmstoffe und deren gebrauch für verfahren zur therapeutischen behandlung; gentherapie und bereitstellung von hemmstoffen, die als pseudosubstrate wirken - Google Patents

Integrin-gekoppelte kinase, ihre hemmstoffe und deren gebrauch für verfahren zur therapeutischen behandlung; gentherapie und bereitstellung von hemmstoffen, die als pseudosubstrate wirken

Info

Publication number
ATE465261T1
ATE465261T1 AT96938869T AT96938869T ATE465261T1 AT E465261 T1 ATE465261 T1 AT E465261T1 AT 96938869 T AT96938869 T AT 96938869T AT 96938869 T AT96938869 T AT 96938869T AT E465261 T1 ATE465261 T1 AT E465261T1
Authority
AT
Austria
Prior art keywords
inhibitors
pseudosubstrates
integrin
provision
action
Prior art date
Application number
AT96938869T
Other languages
English (en)
Inventor
Shoukat Dedhar
Greg Hannigan
Original Assignee
Sunnybrook & Women S College H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunnybrook & Women S College H filed Critical Sunnybrook & Women S College H
Application granted granted Critical
Publication of ATE465261T1 publication Critical patent/ATE465261T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT96938869T 1995-12-21 1996-11-19 Integrin-gekoppelte kinase, ihre hemmstoffe und deren gebrauch für verfahren zur therapeutischen behandlung; gentherapie und bereitstellung von hemmstoffen, die als pseudosubstrate wirken ATE465261T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US907495P 1995-12-21 1995-12-21
PCT/CA1996/000760 WO1997023625A1 (en) 1995-12-21 1996-11-19 Integrin-linked kinase, its inhibitors and methods of medical treatment using these inhibitors, gene therapy and pseudo-substrate inhibitors

Publications (1)

Publication Number Publication Date
ATE465261T1 true ATE465261T1 (de) 2010-05-15

Family

ID=21735424

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96938869T ATE465261T1 (de) 1995-12-21 1996-11-19 Integrin-gekoppelte kinase, ihre hemmstoffe und deren gebrauch für verfahren zur therapeutischen behandlung; gentherapie und bereitstellung von hemmstoffen, die als pseudosubstrate wirken

Country Status (9)

Country Link
US (1) US7655780B2 (de)
EP (1) EP0870033B1 (de)
JP (2) JP4194117B2 (de)
AT (1) ATE465261T1 (de)
AU (1) AU717466B2 (de)
CA (1) CA2239151C (de)
DE (1) DE69638166D1 (de)
NZ (1) NZ322401A (de)
WO (1) WO1997023625A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6699983B1 (en) 1995-12-21 2004-03-02 Sunnybrook Health Sciences Centre Integrin-linked kinase and its uses
ATE465261T1 (de) 1995-12-21 2010-05-15 Sunnybrook & Women S College H Integrin-gekoppelte kinase, ihre hemmstoffe und deren gebrauch für verfahren zur therapeutischen behandlung; gentherapie und bereitstellung von hemmstoffen, die als pseudosubstrate wirken
US6177273B1 (en) * 1999-10-26 2001-01-23 Isis Pharmaceuticals Inc. Antisense modulation of integrin-linked kinase expression
FR2801318A1 (fr) * 1999-11-23 2001-05-25 Centre Nat Rech Scient Nouvelle kinase liee aux integrines ilk-2
DE10024171A1 (de) * 2000-05-17 2001-12-20 Basf Lynx Bioscience Ag Neuronale Serin-Threonin-Protein-Kinase
GB0022333D0 (en) * 2000-09-12 2000-10-25 Glaxo Group Ltd Methods for identifying modulators of protein interactions
US7504228B2 (en) * 2001-06-05 2009-03-17 Qlt Inc. Integrin linked kinase modulation of monocyte activation
EP1448191A1 (de) 2001-11-30 2004-08-25 Kinetek Pharmaceuticals, Inc. Ilk inhibitoren zur behandlung von nierenerkrankungen
AU2002951561A0 (en) * 2002-08-20 2002-10-03 Royal Women's Hospital Marker for early stage cancer screening
WO2005083437A1 (en) * 2004-02-26 2005-09-09 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with integrin-linked kinase 2 (ilk2)
US7531318B2 (en) 2004-08-20 2009-05-12 Board Of Regents, The University Of Texas System Screening of agents for activity against ischemic myocardial insults
CA2609937A1 (en) * 2005-05-27 2006-11-30 The Hospital For Sick Children Modulation of the integrin linked kinase signaling pathway to promote cardiac cell proliferation and self-renewal
US11007528B2 (en) 2010-10-08 2021-05-18 Cellanyx Diagnostics, Llc Systems, methods and devices for measuring growth/oncogenic and migration/metastatic potential
CA2814067A1 (en) * 2010-10-08 2012-04-12 Ashok C. Chander Systems, methods, and devices for measuring growth/oncogenic potential and migration/metastatic potential
WO2014023819A1 (en) * 2012-08-10 2014-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time of a patient suffering from a glioblastoma

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2116460A1 (en) * 1993-03-02 1994-09-03 Mitsubishi Chemical Corporation Preventive or therapeutic agents for alzheimer's disease, a screening method of alzheimer's disease and tau-protein kinase i originated from human being
US5459036A (en) * 1993-03-19 1995-10-17 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Extracellular signal-regulated kinase, sequences, and methods of production and use
JPH10502270A (ja) 1994-06-28 1998-03-03 クロージャー メディカル コーポレイション ｐＨ修整した生体適合性モノマー及びポリマー組成物
US5736381A (en) * 1995-05-19 1998-04-07 Davis; Roger J. Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases
US6001622A (en) * 1995-12-21 1999-12-14 Sunnybrook Health Science Centre Integrin-linked kinase and its use
ATE465261T1 (de) 1995-12-21 2010-05-15 Sunnybrook & Women S College H Integrin-gekoppelte kinase, ihre hemmstoffe und deren gebrauch für verfahren zur therapeutischen behandlung; gentherapie und bereitstellung von hemmstoffen, die als pseudosubstrate wirken

Also Published As

Publication number Publication date
JP2008086314A (ja) 2008-04-17
DE69638166D1 (de) 2010-06-02
US20080039419A1 (en) 2008-02-14
AU717466B2 (en) 2000-03-30
CA2239151A1 (en) 1997-07-03
CA2239151C (en) 2011-03-29
AU7614696A (en) 1997-07-17
EP0870033A1 (de) 1998-10-14
EP0870033B1 (de) 2010-04-21
NZ322401A (en) 2000-02-28
US7655780B2 (en) 2010-02-02
JP2001515344A (ja) 2001-09-18
JP4194117B2 (ja) 2008-12-10
WO1997023625A1 (en) 1997-07-03

Similar Documents

Publication Publication Date Title
EP0788307A4 (de) Oligonukleotidmodulation von multidrogenresistenz-assoziertem protein
ATE465261T1 (de) Integrin-gekoppelte kinase, ihre hemmstoffe und deren gebrauch für verfahren zur therapeutischen behandlung; gentherapie und bereitstellung von hemmstoffen, die als pseudosubstrate wirken
FI973467A0 (fi) DNA-molekyylejä, valmistus ja käyttö geeniterapiassa
NO965080D0 (no) Antisens oligonukleotidmodulering av genekspresjon
ATE239090T1 (de) Methode zum generieren von einzelsträngigen dna molekülen
FI951612A0 (fi) Menetelmiä synteettisten oligonukleotidien sekvensoimiseksi, jotka sisältävät nukleotidien välisiä ei-fosfodiesterisidoksia
ATE334657T1 (de) Hemmung der bcl-2 protein expression durch liposomale antisense-oligodeoxynukleotide
DE69433626D1 (de) N-2 substituierte purine
DE69403642D1 (de) 7-deazapurin modifizierte oligonukleotide
DE3855864D1 (de) Durch modifikationen an der 3'-terminalen phosphodiesterbindung stabilisierte dna moleküle, ihre verwendung als nukleinsäuresonden sowie als therapeutische mittel zur hemmung der expression spezifischer zielgene
DK1053313T3 (da) Optimerede antisense oligonucleotider komplementære til DNA methyltransferase-sekvenser
DE69332668D1 (de) Beeinflussing der zelladhäsie durch oligonukleotide
WO1998054313A3 (en) Dna methyltransferase genomic sequences and antisense oligonucleotides
DE68926455D1 (de) Verfahren zur identifizierung von bakterien
AU2180501A (en) Novel DNA polymerase inhibitors, mikanolide and dihydromikanolide
WO1997024974A3 (en) Compositions and methods for diagnosis of mutation in the von hippel-lindau tumor suppressor gene
ATE321308T1 (de) Verfahren zur auswahl von oligonukleotiden mit niedriger kreuzhybridisierung
DE69430740D1 (de) ANTISENSE OLIGONNUKLEOTIDE DIE MIT DER mRNA CAP AKTIVITÄT INTERFERIEREN UND DIE TRANSLATION INHIBIEREN
ATE391777T1 (de) Verwendung von prohibitin-rns in krebsbehandlung
DE69637171D1 (de) Zusammensetzungen zur gentherapie die nukleinsäure-beladenen polymer-mikropartikeln enthalten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties